Pfizer says its former global marketing director emailed and copied hundreds of documents on product launch plans and steps to obtain government approvals before leaving the company in January.

The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.